Korsana Biosciences, Inc.
Cyclerion is a biopharmaceutical company focused on developing potential treatments for serious neuropsychiatric disorders, with treatment-resistant depression as its lead indication. Its main development program is CYC-126, a potential anesthetic-based therapy that combines propofol and dexmedetomidine with a personalized delivery system that monitors brain activity to support individualized dosing. The treatment is intended for hospital-based settings. Cyclerion also holds legacy soluble guanylate cyclase stimulator assets, including praliciguat, which it has licensed to Akebia, and olinciguat, for which it is exploring licensing opportunities. It seeks to generate income from licensing its legacy assets, including milestone payments and royalties, and may pursue other collaborations or transactions involving them. Cyclerion is headquartered in Waltham, Massachusetts.
No SEC Form 4 filings for $KRSA in the last 30 days.
See all $KRSA insider activity →Korsana Biosciences reported a wider net loss of $46.43M in 3Q 2026, up 113.7% YoY, due to increased R&D and administrative expenses. EPS was ($3.19). The company plans regulatory filings for KRSA-028 and expects pharmacokinetic data in 2027. Cash reserves total $456.2M, expected to last into 2029.
Korsana Biosciences, Inc. (KRSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept dat
Wedbush initiated coverage on Korsana Biosciences (NASDAQ:KRSA) with an Outperform rating and a $44.00 price target, citing potential in its Alzheimer’s disease treatment KRSA-028. The stock, currently at $30.49, has seen significant gains but is considered overvalued by some analysts. Wedbush expects Phase 1 data in mid-2027 and potential revenue of $1.192 billion by 2035. Other analysts have also initiated coverage with buy ratings and varying price targets.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning KRSA (Korsana Biosciences, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent KRSA coverage spans financial news, earnings and corporate actions.
The larger-than-expected loss and increased expenses suggest downward pressure on the stock.
The merger and sizable capital raise strengthen balance sheet and pipeline, likely supporting upside.
Analyst initiation and a higher price target suggest upside potential for KRSA.
Korsana Biosciences, Inc. (CYCN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concep
Cyclerion Therapeutics, Inc. (CYCN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders In connection with the Merger, Cyclerion held an annual meeting of Cyclerion shareholders on August 26, 2026 (the “Shareholder Meeting”), at which the Company’s shareholders voted on the proposals set forth below relat
AlphAI scores every news story that mentions KRSA with an AI model for sentiment and relevance, and aggregates insider trades from Korsana Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Korsana Biosciences reported a wider net loss of $46.43M in 3Q 2026, up 113.7% YoY, due to increased R&D and administrative expenses. EPS was ($3.19). The company plans regulatory filings for KRSA-028 and expects pharmacokinetic data in 2027. Cash reserves total $456.2M, expected to last into 2029.
Korsana Biosciences, Inc. (KRSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept dat
Wedbush initiated coverage on Korsana Biosciences (NASDAQ:KRSA) with an Outperform rating and a $44.00 price target, citing potential in its Alzheimer’s disease treatment KRSA-028. The stock, currently at $30.49, has seen significant gains but is considered overvalued by some analysts. Wedbush expects Phase 1 data in mid-2027 and potential revenue of $1.192 billion by 2035. Other analysts have also initiated coverage with buy ratings and varying price targets.
Korsana Biosciences, Inc. (CYCN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concep
Cyclerion Therapeutics, Inc. (CYCN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders In connection with the Merger, Cyclerion held an annual meeting of Cyclerion shareholders on August 26, 2026 (the “Shareholder Meeting”), at which the Company’s shareholders voted on the proposals set forth below relat
Cyclerion Therapeutics (CYCN) has received positive FDA feedback to advance its investigational therapy, CYC-126, into a Phase 2 study for treatment-resistant depression (TRD). The company plans to initiate the study in the second half of 2026, leveraging a design that incorporates real-time EEG feedback and algorithm-guided dosing. An advisory board has been formed to provide strategic guidance for the development of CYC-126.
CAMBRIDGE, Mass., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology ( "MIT" ) , securing the intellectual property that will serve as the cornerstone of its strategic ...
Cyclerion has entered into a licensing agreement with MIT, securing the intellectual property that will serve as the cornerstone of its strategic relaunch.
